GRI

GRI Bio

• TipRanks·2d ago

  GRI Bio Stockholders Approve Directors and Equity Plan Amendment

• TipRanks·10/13 15:15

  Bristol Phase 3 win underscores opportunity for GRI Bio, says H.C. Wainwright

• Dow Jones·09/10 17:34

  GRI Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

• TipRanks·09/08 12:55

  GRI Bio announces new translational biomarker data from GRI-0621-IPF-02 study

• TipRanks·09/08 12:47

  GRI Bio Reports Positive Phase 2a IPF Biomarker Data

• Dow Jones·08/24 09:54

  GRI Bio Is Maintained at Buy by Ascendiant Capital

• Dow Jones·08/24 09:54

  GRI Bio Price Target Cut to $27.00/Share From $32.00 by Ascendiant Capital

• TipRanks·06/18 23:11

  GRI Bio Secures FDA Orphan Drug Status for IPF

• TipRanks·06/18 13:05

  GRI Bio announces U.S. FDA granted ODD to GRI-0621

• TipRanks·06/17 15:00

  GRI Bio granted FDA orphan designation for tazarotene

• TipRanks·06/03 12:44

  GRI Bio (GRI) Gets a Buy from Ascendiant

• Dow Jones·06/01 10:38

  GRI Bio Is Maintained at Buy by Ascendiant Capital

• Dow Jones·06/01 10:38

  GRI Bio Price Target Cut to $32.00/Share From $40.00 by Ascendiant Capital

• Seeking Alpha·05/14 18:31

  GRI Bio reports Q1 results

• TipRanks·05/14 13:02

  GRI Bio Highlights Promising Phase 2a IPF Data, Outlook